J&J’s ‘Pretzel’ Drug-Device Combo Scores in Mid-Stage Bladder Cancer Study

Johnson & Johnson on Friday unveiled updated data from its Phase IIb SunRISe-1 study, which found that its investigational drug-device combination TAR-200 can induce rapid complete response in patients with high-risk non-muscle invasive bladder cancer.